Data from the ALLEGRO study of Teva’s Laquinimod will be presented on a webcast April 14: http://finance.yahoo.com/news/Teva-Announces-Webcast-on-bw-1372651538.html?x=0&.v=1 The second phase-3 Laquinimod study (BRAVO) is due to report data in 3Q11.